Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Shareholder vote
confidence 75%
filed 2026-06-23
EX-99.1
The exhibit is a press release announcing results of Skeena's Annual General Meeting held June 22, 2026, disclosing shareholder approval of director reelection, the Rolling Omnibus Incentive Plan, auditor reappointment, and board size. The detailed voting table shows voting percentages for each director nominee. While the exhibit also includes management changes (appointment of Ryan Maloney as VP Corporate Development and transition of Justin Himmelright to Strategic Advisor), the primary disclosed event is the AGM vote results, which is material to investors as it confirms board composition and governance approvals. The management changes are secondary announcements within the same release.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This press release announces positive metallurgical test results for the Ninaaskumuwin lithium discovery on Fury's Elmer East project, demonstrating feasibility of producing a Direct Shipping Ore concentrate grading 6.024% Li₂O with 76.66% recovery through Dense Media Separation. The disclosure is a material operational/exploration milestone that would affect a reasonable investor's assessment of the company's lithium asset value and development potential, but does not fit the specific event categories (it is neither an earnings release, M&A activity, nor a discrete financial obligation).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
Anika Therapeutics held its Annual Meeting on June 18, 2026, with stockholders voting on five proposals: election of three Class III directors (Fischetti, Henneman, Griffin), ratification of Deloitte & Touche LLP as auditor, advisory approval of named executive officer compensation, approval of the Revised Seventh Amended Plan increasing equity reserves, and amendment of the ESPP increasing share reserves. The filing reports the final voting results for each proposal.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-23
EX-99.2
Westport completed a registered direct offering of 1.6 million common shares and 3.25 million pre-funded warrants, combined with a concurrent private placement of 4.85 million warrants, raising approximately US$10 million in gross proceeds with potential for an additional US$10 million upon warrant exercise. The offering involved both registered and unregistered securities (private placement warrants under Section 4(a)(2) and Regulation D), materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
The filing discloses a conditional $17.5 billion DOE financing commitment to support Westinghouse nuclear reactor deployment, in which Brookfield holds a 51% ownership stake. This is a material operational and strategic development affecting Brookfield's nuclear energy business, but it is conditional and does not constitute a completed transaction or M&A activity. The event is best classified as an operational milestone rather than a specific financial or governance category.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-06-23
EX-99.1
This exhibit is a Notice of Special Meeting of Shareholders and accompanying Proxy Statement soliciting shareholder approval for one or more reverse stock splits at a cumulative exchange ratio between one-for-two and one-for-250. While reverse stock splits are governance matters requiring shareholder approval, this is a pre-vote notice and proxy solicitation document, not a shareholder vote result. The disclosure is material because reverse stock splits affect share structure and trading price, and the company explicitly notes NASDAQ listing compliance concerns (minimum $1.00 bid price requirement). This is a governance event that does not fit the specific `shareholder_vote_results` category (which applies post-vote) but is clearly governance-related and material to investors.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 65%
filed 2026-06-23
EX-99.1
The press release announces a 1-for-25 reverse stock split effective June 26, 2026, reducing outstanding shares from ~15.1 million to ~605,000. While a reverse split itself is not a new issuance, it is a capital structure event that signals potential delisting risk mitigation—the Company explicitly states the purpose is "to maintain compliance with Nasdaq's continued listing requirements," suggesting the stock price had fallen below minimum thresholds. This is material to investors as it reflects compliance pressure and dilution concerns, though the classification is somewhat ambiguous between `dilutive_issuance` (capital structure change affecting share value) and `delisting_risk` (the underlying compliance issue). The reverse split is the disclosed action, making `dilutive_issuance` the best fit, though confidence is moderate given the reverse split itself does not create new shares.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-06-23
EX-99.1
This press release announces the filing and mailing of meeting materials for a special shareholder meeting to approve a business combination (plan of arrangement) between Equinox Gold and Orla Mining. The transaction involves Equinox Gold acquiring all outstanding common shares of Orla Mining, with each Orla share exchanged for 1.00 Equinox Gold common share and US$0.0001 in cash, resulting in a combined company where existing Equinox Gold and former Orla shareholders will own approximately 67% and 33%, respectively. This is a material acquisition and change of control event requiring shareholder approval.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-23
EX-99.1
This Material Change Report discloses operational disruptions at Alamos Gold's Young-Davidson mine caused by seismic events (June 12, 2026) and power outages (May 2026), resulting in revised production guidance downward by 12% for Q2 2026 and expectations that full-year 2026 consolidated production will fall below the low end of prior guidance with costs above guidance. While the disclosure includes operational updates on Island Gold District and hedging activities, the material event is the operational disruption and associated guidance revision, which is an operational matter affecting production and costs rather than a discrete event type like impairment or restructuring.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-06-23
EX-99.1
Allot's Board of Directors has authorized a $40 million share repurchase program, which is a return of capital to shareholders. The announcement explicitly states the program "reflects the Board's confidence in Allot's long-term growth strategy, strong financial position" and CEO Harari characterizes it as "an attractive use of our excess capital, that allows us to create increased value for our shareholders." Share repurchases are a form of capital distribution and would materially affect a reasonable investor's assessment of capital allocation and shareholder value creation.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-23
The 6-K announces the appointment of two directors, Mr. Erez Wiener and Mr. Daniel Schutz, effective July 1, 2026. This is a clear executive/governance appointment. The disclosure includes detailed biographical information for both appointees, including Wiener's prior service as CEO of the Company and Schutz's family relationship to the CEO and controlling shareholder Joseph Williger, making this material to investors' assessment of board composition and potential conflicts of interest.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-06-23
The Company entered into a Securities Purchase Agreement on June 23, 2026, to issue a convertible promissory note ($1.5M principal at initial closing, up to $2M total) and warrants to purchase 468,978 Class A ordinary shares. The convertible note and warrant structure creates significant dilution to existing shareholders through conversion and exercise rights. This is a classic PIPE-like transaction raising capital through unregistered securities with conversion/exercise features, fitting the dilutive_issuance taxonomy.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-06-23
EX-99.1
The exhibit announces a 30-for-1 reverse stock split effective June 23, 2026, explicitly stated as "primarily intended to bring the Company into compliance with the $1.00 minimum bid price requirement for maintaining its Nasdaq listing." This disclosure directly addresses delisting risk and the company's remedial action to avoid loss of listing status, which is material to investors assessing the registrant's continued market access and trading liquidity.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
PRA Group held its 2026 Annual Meeting of Stockholders on June 16, 2026, with voting results on four matters: election of nine directors, ratification of Ernst & Young LLP as independent auditor, advisory vote on named executive officer compensation, and amendment to the 2022 Omnibus Incentive Plan increasing share authorization by 3,500,000 shares.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-06-23
EX-99
Exhibit 99.1 and 99.2 announce a cash dividend adjustment and record date. The company adjusted the per-share dividend from NT$2.60 to NT$2.60808262 due to share repurchases and restricted stock cancellations, with a payment date of 2026/07/30. This is a material dividend distribution event affecting shareholders.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
ChipMOS disclosed the acquisition of plant engineering works and equipment accessories from MAU TSWEN MECHANICAL ENGINEERING CO., LTD. for NT$512,231 thousand (approximately $16.5 million USD), completed between July 2, 2025 and June 23, 2026. The transaction was approved by the Company President on June 23, 2026, and is disclosed pursuant to Taiwan Stock Exchange material information disclosure rules. While this is a capital asset acquisition for manufacturing purposes rather than a business combination or M&A activity, the substantial amount and operational significance of acquiring plant and equipment warrant classification as a material operational event that would affect a reasonable investor's assessment of the company's capital deployment and operational capacity.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-06-23
EX-99
This is a press release announcing Jiayin Group's unaudited financial results for Q1 2026, dated June 23, 2026. The exhibit discloses quarterly financial performance including net revenue of RMB 756.7 million (down 57.4% YoY), a net loss of RMB 61.7 million (versus net income of RMB 539.5 million in Q1 2025), transaction volume of RMB 19.3 billion (down 45.8% YoY), and detailed consolidated balance sheets and statements of comprehensive income. The dramatic revenue decline, shift from profitability to loss, and significant operational deterioration are material to investors' assessment of the company's financial condition and performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
Paramount Gold announced completion of a Technical Report Summary Initial Assessment (S-K 1300 compliant) for the Sleeper Gold Project, a past-producing mine, disclosing positive project economics with after-tax NPV of $402M–$867M and IRR of 45–66%, along with an updated mineral resource estimate showing a 5% increase in Measured & Indicated Resources and 90% increase in Inferred Resources. The company plans to advance toward production restart with an $8.7M advancement program and permitting activities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder voting results from an annual and special meeting held on June 22, 2026. The filing reports the outcomes of three proposals: fixing the board size at seven directors, electing seven director nominees, and appointing PricewaterhouseCoopers LLP as independent auditor. All proposals were approved with detailed vote tallies provided for each matter, which is the quintessential content of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
EX-99.1
PLDT discloses that VITRO Inc. (a wholly-owned subsidiary of ePLDT, itself a wholly-owned subsidiary of PLDT) has submitted an application for listing on the Philippine Stock Exchange Main Board in connection with a proposed initial public offering. This is a material operational and strategic event—a subsidiary's IPO would affect PLDT's capital structure, ownership stake, and financial position—but does not fit the specific categories of M&A activity (which typically involves acquisition or disposition of assets/control), dilutive issuance (which applies to the parent issuer's own equity), or other named types. The disclosure is clearly operational/strategic in nature, making `operational_other` the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-23
Item 8.01
Phathom announced completion of enrollment in its Phase 2 pHalcon-EoE-201 clinical trial for VOQUEZNA in eosinophilic esophagitis, with 95 patients enrolled at 41 U.S. sites and topline results anticipated in Q4 2026. This is a material operational/clinical milestone for a biopharmaceutical company's drug development program, but does not fit the specific categories of earnings release, M&A, impairment, litigation, or other named event types. The disclosure is material to investors assessing the company's pipeline progress and regulatory prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-23
Item 7.01
LM Funding announced a strategic expansion into high-performance computing and AI infrastructure, including orders for GPU hardware and marketing of 10 megawatts of available power capacity to AI customers, with potential $20M–$50M annual revenue opportunity. This represents a material pivot from the company's primary Bitcoin mining business, leveraging its existing 26-megawatt power infrastructure to enter a new business line.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-06-23
Item 1.01
Boundless Bio entered into a definitive merger agreement with Serapha Bio, whereby Serapha will be the surviving entity and Boundless stockholders will own approximately 3.7% of the combined company post-closing. The transaction includes a concurrent $230 million private placement financing and is expected to close in Q4 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Serapha Bio is raising $230 million through a private placement of capital stock in connection with the proposed merger, with approximately $138 million already funded in a Series A financing and $92 million expected to close concurrently with the merger closing.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-06-23
Item 2.05
In connection with the merger agreement, Boundless Bio announced a workforce reduction of approximately 75% of its workforce, with estimated one-time costs of $3.0–$5.0 million primarily for termination benefits and severance, substantially completed in Q3 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-23
Item 5.02
In connection with the merger transaction, Oien was appointed as President and principal executive officer of Boundless Bio, replacing departing CEO Hornby, along with compensatory arrangements including transaction bonuses and acceleration of stock options.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-23
Item 5.02
Wendy's appointed Steven W. Cirulis as Chief Financial Officer and Chief Strategy Officer effective June 23, 2026, with a $675,000 base salary, 90% bonus target, and $1,650,000 annualized LTIP grant. Ken Cook departed the CFO role effective July 31, 2026, transitioning to an advisory capacity.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 99%
filed 2026-06-23
Item 1.03
Sangamo Therapeutics filed a voluntary petition for relief under Chapter 11 of the Bankruptcy Code on June 23, 2026 (Case No. 26-10989) in the U.S. Bankruptcy Court for the District of Delaware. The company will operate as a debtor-in-possession and has filed motions for first-day relief and debtor-in-possession financing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-06-23
Item 1.01
In connection with its Chapter 11 bankruptcy proceedings, Sangamo entered into stalking horse asset purchase agreements, a mechanism used in bankruptcy proceedings to facilitate asset sales and disposition activities.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-06-23
Item 2.03
Sangamo disclosed the creation of a debtor-in-possession (DIP) financing facility of up to $30 million from Northridge ATM, LLC, which constitutes a new direct financial obligation subject to court approval.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-06-23
Item 2.05
The Board approved a restructuring eliminating approximately 51 roles (40% of workforce) with expected incremental expenses of $3.0–$4.0 million in severance and employee health benefits.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-06-23
Item 8.01
The filing discloses that the HSR Act waiting period for a previously announced merger between TruBridge and Inventurus Knowledge Solutions expired on June 22, 2026, removing a key closing condition. The merger involves Merger Sub merging with TruBridge, with TruBridge becoming a wholly owned subsidiary of Parent—a material change of control transaction. This is a significant milestone in the completion of a material acquisition/merger.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This Item 5.07 discloses the results of MiNK Therapeutics' Annual Meeting of Stockholders held on June 17, 2026, including the election of three Class II Directors (Garo Armen, Barbara Ryan, and John Holcomb) and ratification of KPMG LLP as independent auditor. The filing presents detailed voting tallies for each proposal, which is the core disclosure required under Item 5.07 for shareholder vote results.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of Agenus Inc.'s Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting outcomes for six proposals: election of Class II Directors (Garo Armen and Jennifer Buell), approval of amendments to equity plans, a stock option exchange program, advisory compensation vote, and auditor ratification. All proposals were approved by stockholders, with detailed vote tallies provided for each matter. This is a material governance event affecting investor understanding of board composition and equity incentive structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Stepstone Private Credit Fund LLC completed an unregistered sale of 10,650,045 LLC interests for $279.6 million pursuant to subscription agreements, relying on Section 4(a)(2), Regulation D, and Regulation S exemptions. This private placement materially affects the registrant's capitalization and ownership structure.
View raw filing on EDGAR →
8-K
Financial Other
confidence 65%
filed 2026-06-23
Item 8.01
The filing discloses the Company's net asset value per share ($26.25 as of May 31, 2026), aggregate NAV ($2,536.7 million), portfolio fair value, debt outstanding, and the status of an ongoing private offering ($2,689.0 million raised to date toward a $10 billion target). These metrics are material to investors in the closed-end fund structure but do not constitute a discrete event fitting standard 8-K categories.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a clear disclosure of shareholder vote results from the 2026 Annual Meeting of Stockholders held on June 19, 2026. The filing reports voting outcomes for two proposals: (1) election of eleven directors with detailed vote tallies for each nominee, and (2) advisory approval of named executive officer compensation. This is a quintessential Item 5.07 disclosure and is material to investors as it reflects governance decisions and shareholder sentiment on board composition and executive compensation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-23
EX-99.1
This news release announces the US Department of Energy's conditional commitment of up to US$17.5 billion in loan financing to support Westinghouse's procurement of long-lead items for up to 10 AP1000 nuclear reactors. While the DOE commitment is conditional and subject to satisfaction of technical, legal, environmental, and financial conditions, the announcement represents a material strategic development for Cameco's ownership stake in Westinghouse (acquired November 2023) and signals significant near-term business opportunities in reactor deployment and nuclear fuel supply. This is an operational/strategic milestone rather than a discrete M&A transaction, earnings release, or other named event type, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-23
Item 5.02
The filing discloses both a departure (James J. Lorenz retiring effective December 31, 2026) and an appointment (John T. Robson appointed Vice President – Energy Operations effective January 1, 2027). While both events are present, the principal forward-looking action and the substantive disclosure centers on the appointment of Robson to succeed Lorenz in a key operational role. The appointment is the material event that addresses continuity of leadership in Energy Operations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-06-23
Item 3.02
Vista Credit Strategic Lending Corp. completed an unregistered sale of 147,178.274 shares of Class I and Class S common stock for $2,808,500 pursuant to subscription agreements, relying on Section 4(a)(2) and Regulations D and S exemptions.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-06-23
Item 8.01
The Company disclosed preliminary net asset value (NAV) per share of $19.08 as of May 31, 2026, along with total investments of $1.9 billion and a debt-to-equity ratio of 0.83x.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-06-23
Item 5.07
First Eagle Private Credit Fund held its 2026 Annual Meeting of Shareholders on June 17, 2026, with shareholders voting to elect two Class I trustees (Nancy Hawthorne and Patrick Coyne, each receiving 12,403,652 votes for with zero withheld) and ratify PricewaterhouseCoopers LLP as independent auditor (12,403,652 votes for, zero against, zero abstained).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-06-23
Item 7.01
First Eagle Private Credit Fund declared regular distributions to shareholders of $0.210 per share (gross) for both Class I and Class D common shares, with a record date of June 30, 2026 and a payment date of July 30, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-06-23
Item 1.01
Fiserv completed a public offering of €1 billion in aggregate principal amount of senior notes, consisting of €500 million 3.750% Notes due 2030 and €500 million 4.250% Notes due 2034, on June 23, 2026. This represents a material creation of direct financial obligations with defined interest rates and maturity dates.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-06-23
Item 2.03
FMC entered into Amendment No. 7 to its Fifth Amended and Restated Credit Agreement on June 16, 2026, which materially modifies the limitation on liens and releases security interests on collateral previously granted to secure obligations under the Credit Agreement. This amendment represents a material modification of the Company's direct financial obligations and credit arrangements, affecting collateral and lien restrictions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
This is a classic Item 5.07 disclosure reporting the results of LeonaBio's 2026 Annual Meeting of Stockholders held on June 22, 2026. The filing presents final voting tallies for four proposals: election of three Class III directors (Kelly A. Romano, James A. Johnson, and Natalie Holles), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and advisory vote on the frequency of future say-on-pay votes (determined to be every 3 years). The disclosure includes vote counts, broker non-votes, and the Board's determination based on the results, which is the standard format for shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-06-23
Item 5.07
IDEAYA held its 2026 Annual Meeting of Stockholders on June 16, 2026, with shareholders voting on three proposals: election of three Class I directors, ratification of PricewaterhouseCoopers LLP as independent auditor, and a non-binding advisory vote on named executive officer compensation. The filing reports the tabulated vote counts for each proposal.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-06-23
Item 8.01
Effective June 16, 2026, the Board elected Yujiro S. Hata as Chairman of the Board and Terry Rosen, Ph.D., as Lead Independent Director, representing material governance restructuring of board leadership and oversight roles.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 8.01
William Go, M.D., Ph.D., Chief Medical Officer of Janux Therapeutics, departed on June 23, 2026, under a termination without "Cause" under the Company's Change in Control and Severance Benefit Plan. The disclosure centers on the departure of a named executive officer and the triggering of severance benefits, making this a clear executive departure event. The company's statement that the transition does not affect development strategy or clinical timelines is a standard mitigation statement but does not change the materiality of the CMO's departure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-23
Item 5.02
The filing discloses both the departure of Nelson Haight as Executive Vice President and Chief Financial Officer and the appointment of Clinton Roeder to the same role, effective June 22, 2026. While both events are disclosed, the appointment of a new CFO with detailed compensation terms (base salary of $500,000, bonus target of 75%, and equity grants of approximately $500,000) is the forward-looking material event that would affect investor assessment of the company's leadership and financial management going forward. The appointment is the principal action the company is announcing to the market.
View raw filing on EDGAR →